The results of a phase 2 trial of MSD’s ROR1 inhibitor zilovertamab vedotin (zilo-V) back up the company's decision to push the antibody-drug conjugate (ADC) into a phase 3 programme.

MSD has started a phase 3 trial of ROR1-directed zilovertamab vedotin (zilo-V) as a treatment for previously untreated diffuse large B-cell lymphoma (DLBCL), cementing the antibody-drug conjugate ...

Zilovertamab vedotin (ZV) is a novel ROR1-targeting antibody-drug conjugate that has shown promising efficacy in patients with DLBCL. Here we present results of the dose confirmation part of the ...

Zilovertamab vedotin is an ADC that targets ROR1, which is a transmembrane protein overexpressed in multiple haematologic malignancies. The ADC market was valued at $8.6bn in 2023, ...

Background: ROR1 is an oncofetal protein expressed in various blood and solid cancers. Zilovertamab vedotin (ZV) is an antibody-drug conjugate comprising a monoclonal antibody against ROR1, a ...

Zilovertamab vedotin is an investigational, potential first-in-class antibody drug conjugate (ADC) that targets receptor tyrosine kinase-like orphan receptor 1 (ROR1). At a pre-planned analysis, ...

Our most advanced pipeline programs are varegacestat (formerly AL102), a gamma secretase inhibitor which is currently in a Phase 3 trial for treatment of desmoid tumors; IM-1021, a ROR1-targeted ...

Gallup Municipal Airport (GUP), 87301, United States: Airport Type : Public: Owner : City of Gallup: Timezone : America/Denver: Senator Clark Airport Timezone : GMT -06:00 hours: Current time and date ...

Ted Gup, "Owl vs. Man," Time (June 25, 1990), pp. 56-62. This article was originally published in Issues in Ethics - V. 4, N. 1 Spring 1991. Nov 13, 2015-- Environmental Ethics Sections Environmental ...

Zilovertamab vedotin is an ADC that targets ROR1, which is a transmembrane protein overexpressed in multiple haematologic malignancies. The ADC market was valued at $8.6bn in 2023, with it forecast to ...